Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03650894|
Recruitment Status : Recruiting
First Posted : August 29, 2018
Last Update Posted : December 23, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Breast Neoplasm Female Breast Cancer Breast Carcinoma Breast Tumor||Drug: Nivolumab Drug: Ipilimumab Drug: Bicalutamide||Phase 2|
This is a phase II trial to assess the clinical efficacy and safety of nivolumab (anti-Programmed Death receptor-1, or anti-PD-1) combined with bicalutamide (Androgen Receptor (AR) inhibitor) and ipilimumab (anti-cytotoxic T-lymphocyte-associated protein 4, or anit-CTLA4) in patients with advanced breast cancer.
This study will include adult women with metastatic or locally advanced unresectable Human Epidermal Growth Factor (HER2)-negative breast cancer (by National Comprehensive Cancer Network (NCCN) criteria). Triple-negative breast cancer tumors will require confirmation of AR positivity at screening. Participants will have had no more than one line of previous chemotherapy in non-curative setting; subjects with metastatic progression within 1 year following completion of curative-intent chemotherapy are eligible if they have not received any additional lines of systemic therapy in the non-curative setting.
Women who meet all of the study inclusion criteria, none of the study exclusion criteria, and agree to participate will receive a combination of the following:
- Intravenous nivolumab 240mg, every 2 weeks until progression or unacceptable toxicity
- Intravenous ipilimumab 1mg/kg, every 6 weeks until progression or unacceptable toxicity
- Oral bicalutamide 150mg, daily until progression or unacceptable toxicity
Participants are to be treated for up to 24 months. Patients who have ongoing response will discontinue ipilimumab and nivolumab after 24 months, but at the discretion of the investigator may continue bicalutamide, and will continue assessments as per standard of care. Any patient who subsequently progresses will have the option to resume treatment upon disease progression.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||138 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||This is a phase II open-label study of nivolumab combined with ipilimumab and bicalutamide for HER2-negative metastatic or unresectable breast cancer.|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Study of Nivolumab Combined With Bicalutamide and Ipilimumab in Metastatic HER2-negative Breast Cancer|
|Actual Study Start Date :||April 3, 2019|
|Estimated Primary Completion Date :||April 2024|
|Estimated Study Completion Date :||April 2025|
Experimental: Nivolumab, Ipilimumab, and bicalutamide
Participants will receive nivolumab plus ipilimumab combination therapy. Participants should receive nivolumab at a dose of 240 milligrams (mg) fixed dose as a 30-minute intravenous (IV) infusion prepared in 50 milliliter (ml) normal saline (NS) every 2 weeks until progression. Participants should receive ipilimumab at a dose of 1 mg/kilogram as a 30-minute IV infusion prepared in 50 ml NS every 6 weeks. All subjects will take bicalutamide 150mg (3 x 50mg tablets) daily.
Nivolumab 240 mg IV every 2 weeks
Other Name: Opdivo
Ipilimumab 1 mg/kg IV every 6 weeks.
Other Name: Yervoy
Oral bicalutamide 150mg (3 x 50mg tablets) daily
Other Name: Casodex
- iRECIST Clinical Benefit Rate (the number of patients with objective response or ongoing stable disease at week 24 using iRECIST guidelines) [ Time Frame: 24 weeks ]To assess the 24-week clinical benefit rate of nivolumab combined with bicalutamide and ipilimumab in advanced HER2-negative breast cancers assessed by radiographic criteria (computed tomography (CT) scan or magnetic resonance imaging (MRI) according to iRECIST criteria.
- Assess best overall objective response rate (proportion of patients who achieve a complete or partial response) [ Time Frame: 24 months ]Best overall objective response rate will be assessed by radiographic criteria from CT or MRI scans and will be based on RECIST 1.1 and iRECIST criteria
- Duration of progression free survival [ Time Frame: From first patient enrolled through last patient's progression or 24 months following last patient enrolled, whichever comes first. ]Average length of time between study entry and disease progression or death
- Overall survival rate [ Time Frame: 24 months. ]Number of patients who are alive
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||Female|
|Gender Based Eligibility:||Yes|
|Gender Eligibility Description:||Females, aged 18 or older|
|Accepts Healthy Volunteers:||No|
- ECOG performance status of 0-1;
- Metastatic or locally advanced unresectable HER2-negative breast cancer (by NCCN criteria);
- Triple Negative Breast Cancer tumors will require confirmation of androgen-receptor (AR) positivity at screening (refer to laboratory manual for guidelines). Local testing permitted for eligibility if reviewed by a designated study pathologist;
- RECIST1.1 measurable disease;
- Participants must be willing (if clinically feasible) to provide a fresh tumor biopsy (or archived tissue). For archived tissue, a tissue block from the most recent biopsy is acceptable if no intervening anti-neoplastic therapies have been administered since the time of biopsy.
- Previous systemic chemotherapy: no greater than one line of previous chemotherapy in non-curative setting; subjects with metastatic progression within 1 year following completion of curative-intent chemotherapy are eligible if they have not received any additional lines of systemic therapy in the non-curative setting.
- Participants must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal patient care.
- Participants must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, tumor biopsies, and other requirements of the study
- Adequate hematologic and liver function (using CTCAE v4). (All baseline laboratory requirements will be assessed and should be obtained within 14 days prior to enrollment): WBC≥2000/μL; Neutrophils≥1500/μL; Platelets≥100 × 103/μL; Hemoglobin ≥9.0 g/dL; AST≤3 × ULN; ALT ≤3 × ULN; Total bilirubin ≤1.5 × ULN (except in participants with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL). Subjects with elevations in LFTs related to underlying hepatic cancer involvement may be considered for enrollment (after discussion with lead PI) if ALT/AST is ≤5 x ULN and Total bilirubin ≤3 × ULN.
- Female and Age ≥18 years. (Men are excluded because of potential confounding effects of sex on correlative analyses)
- Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study treatment.
- Women must not be breastfeeding
- Women of childbearing potential (WOCBP) must agree to follow instructions for method(s) of birth regulation for the duration of treatment with study treatment(s) for a total of 5 months post-treatment completion.
- Active brain metastases or leptomeningeal metastases. Participants with brain metastases are eligible if these have been treated and there is no magnetic resonance imaging (MRI except where contraindicated in which CT scan is acceptable) evidence of progression for at least 2 weeks after treatment is complete and within 28 days prior to first dose of study drug administration. Cases must be discussed with the lead PI, Dr. Page. Brain lesions are not considered measurable disease.
- Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, or carcinoma in situ of the cervix. Subjects with prior history of unrelated breast cancer not requiring active therapy may be considered for enrollment, but require discussion with and approval of PI;
- Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the participant to receive protocol therapy, or interfere with the interpretation of study results.
- Participants must have recovered from the effects of major surgery requiring general anesthetic or significant traumatic injury at least 14 days before enrollment.
- Participants with active, known or suspected autoimmune disease. Participants with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
- Participants with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
- Uncontrolled adrenal insufficiency.
- New York Heart Association (NYHA) Functional Classification of Heart Failure: Class III or Class IV
- All toxicities attributed to prior anti-cancer therapy other than alopecia and fatigue must have resolved to Grade 1 (NCI CTCAE version 4) or baseline before administration of study drug. Participants with toxicities attributed to prior anti-cancer therapy which are not expected to resolve and result in long lasting sequelae, such as peripheral neuropathy grade 2 or less, are permitted to enroll
- Known history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, unstable angina pectoris, or psychiatric illness/social situations that would limit obtaining informed consent or compliance with study requirements.
- Participants who have had a history of acute diverticulitis, intra-abdominal abscess, GI obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation.
- Participants with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity.
- Has known active hepatitis B (e.g. HBsAg reactive) or Hepatitis C (e.g. HCV RNA is detected);
- History of allergy or hypersensitivity to study drug components
- Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody in the metastatic setting, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways. Previous treatment with anti-PD-1/L1 in the curative setting is allowed if subjects have not received such therapy within one year of screening.
- Prior treatment with bicalutamide, enzalutamide, or any other androgen receptor blocker.
- Use of an investigational agent within 4 weeks of Day 1 visit
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03650894
|Contact: Larisa Lundgren||(503) 215-2614||Larisa.Lundgren@providence.org|
|Contact: Nicole Moxon, RN||(503) 215-2619||Nicole.Moxon@providence.org|
|United States, New York|
|Memorial Sloan Kettering Cancer Center||Recruiting|
|New York, New York, United States, 10065|
|Contact: Ayca Gucalp, MD|
|Principal Investigator: Ayca Gucalp, MD|
|Sub-Investigator: Ting Bao, MD|
|Sub-Investigator: Victoria Blinder, MD|
|Sub-Investigator: Jacqueline Bromberg, MD, PhD|
|Sub-Investigator: Sarat Chandarlapaty, MD, PhD|
|Sub-Investigator: Elizabeth Comen, MD|
|Sub-Investigator: Gabriella D'Andrea, MD|
|Sub-Investigator: Chau Dang, MD|
|Sub-Investigator: Joshua Drago, MD|
|Sub-Investigator: Carlos Dos Anjos, MD|
|Sub-Investigator: Pamela Drullinsky, MD|
|Sub-Investigator: Monica Fornier, MD|
|Sub-Investigator: Devika Gajria, MD,MPH|
|Sub-Investigator: Shari Goldfarb, MD|
|Sub-Investigator: Neil Iyengar, MD|
|Sub-Investigator: Komal Jhaveri, MD|
|Sub-Investigator: Diana Lake, MD|
|Sub-Investigator: Tomas Lyons, MD|
|Sub-Investigator: Shanu Modi, MD|
|Sub-Investigator: Redram Razavi, MD|
|Sub-Investigator: Mark Robson, MD|
|Sub-Investigator: Ezra Rosen, MD|
|Sub-Investigator: Rachel Sanford, MD|
|Sub-Investigator: Andrew Seidman, MD|
|Sub-Investigator: Nancy Skalarin, MD|
|Sub-Investigator: Tiffany Traina, MD|
|Sub-Investigator: Linda Vahdat, MD|
|Sub-Investigator: Neil Vasan, MD|
|Sub-Investigator: Dariana Espinal, RN|
|Sub-Investigator: Esthefanie Giordano, RN|
|Sub-Investigator: Renee Mercado, RN|
|Sub-Investigator: Karen Suarez, RN|
|Sub-Investigator: Elizabeth Villafane, RN|
|Sub-Investigator: Vanessa Soto-Romano, RN|
|Sub-Investigator: Maureen Cannon, NP|
|Sub-Investigator: Karen Drucker, NP|
|Sub-Investigator: Odessa Williams, NP|
|Sub-Investigator: Nicole Jimenez, NP|
|Sub-Investigator: Melissa Emerzian, NP|
|Sub-Investigator: Mikel Ross, NP|
|Sub-Investigator: Alexa Segna, NP|
|Sub-Investigator: Britni Rizzolo, NP|
|Sub-Investigator: Kathleen Kilcullen, NP|
|Sub-Investigator: Hannah Wen, MD, PhD|
|Sub-Investigator: Amy Deipoly, MD, PhD|
|Sub-Investigator: Mary Hughes, MD|
|Sub-Investigator: Arthur Frauff, MD|
|United States, Oregon|
|Providence Oncology & Hematology Care Clinic - Eastside||Recruiting|
|Portland, Oregon, United States, 97213|
|Sub-Investigator: Rachel Sanborn, MD|
|Sub-Investigator: Alison Conlin, MD|
|Sub-Investigator: Todd Crocenzi, MD|
|Sub-Investigator: Brendan Curti, MD|
|Sub-Investigator: John Godwin, MD|
|Sub-Investigator: Rom Leidner, MD|
|Sub-Investigator: Rui Li, MD, PhD|
|Sub-Investigator: Walter Urba, MD, PhD|
|Principal Investigator: David Page, MD|
|Sub-Investigator: Herschel Wallen, MD|
|Sub-Investigator: Moran Amy, PhD|
|Principal Investigator:||David B. Page, MD||Providence Health & Services|
|Responsible Party:||Providence Health & Services|
|Other Study ID Numbers:||
|First Posted:||August 29, 2018 Key Record Dates|
|Last Update Posted:||December 23, 2022|
|Last Verified:||December 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Her2 negative breast cancer
Neoplasms by Site
Antineoplastic Agents, Immunological
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs